AngioDynamics (ANGO) concentration risks

AngioDynamics carries two high-share dependency exposures that reinforce each other. On the demand side, international distributors accounted for approximately 74% of the company's international revenues — a high concentration within that specific slice of the business, meaning a handful of third-party distribution relationships control the large majority of how AngioDynamics reaches customers outside the United States. On the supply side, the company sources significant amounts of several key products, raw materials, and components from single and limited source suppliers, also a high-share dependency. Both exposures share the same character: counterparty dependency rather than a diversified structural feature of the business. A disruption to a key international distributor could impair a substantial portion of international sales specifically, while a disruption at a sole-source supplier could constrain production of the underlying products themselves — a combination that leaves the company exposed on both the sell side and the supply side of its international and manufacturing operations. Because neither exposure is offset by disclosed diversification elsewhere in the filing, these two high-share dependencies are the dominant concentration story for AngioDynamics and the ones most likely to matter if either relationship deteriorates.

For the engine’s reasoning on ANGO’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.